Not yet covered below? Email info@empowermed.us — our team helps connect you with the appropriate physician and next step.
No. Empower Med is a physician practice that delivers care virtually. Dr. Scott Everson, DO, MPH brings his preventive-medicine expertise to the practice. Your treating physician oversees clinical decisions, laboratory review, and treatment adjustments; the clinical team helps connect you with the appropriate physician and next step.
Dr. Everson is based in Potomac Shores / Dumfries, Virginia and licensed in Virginia. Care is delivered entirely through virtual consultations. Patients must be located in Virginia at the time of care.
No. Empower Med is a 100% virtual practice. Physical presence in a waiting room isn’t what defines the care — the physician-direct relationship is. Virtual consultations connect patients with physician care.
If you want weight-management and metabolic optimization (GLP-1 therapy, nutrition planning, metabolic lab monitoring): Metabolic Optimization.
If you’re a man with declining energy, libido, recovery, or body composition: Male Hormone (TRT).
If you’re a woman in perimenopause, menopause, or beyond: Female Hormone (HRT).
If you have questions about peptides or other emerging longevity treatments: Emerging Therapies explains how Empower Med evaluates evidence, safety, and regulatory status.
If you just want labs with physician interpretation before committing to anything: Open-Access Labs.
Metabolic Optimization is $125/month for ongoing physician-directed care. TRT and HRT are each $149/month. There is no fixed-term contract, and you may cancel at any time.
Continued medication authorization requires active care and required monitoring; additional controlled-substance requirements apply to testosterone.
Open-Access Labs are one-time services with no program enrollment required.
Yes — and often it’s clinically appropriate. Many male patients run Metabolic and TRT in parallel so that weight loss doesn’t come at the cost of muscle mass. When more than one established service line is clinically appropriate, your treating physician manages the combined plan as one clinical picture.
Peptide-based treatments do not share one evidence base or regulatory status. Some medications are FDA-approved for specific indications, while other compounds remain investigational, restricted, or under regulatory review. Empower Med evaluates each therapy individually and does not currently offer BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, injectable GHK-Cu, retatrutide, cagrilintide, or similar emerging compounds.
No. These and several related emerging compounds are not currently offered by Empower Med. We continue to monitor regulatory developments and clinical evidence. Any future offering would require lawful availability, appropriate sourcing, sufficient evidence and safety support, and an individualized physician assessment.
Yes. You may bring questions about a medication, peptide, supplement, or emerging therapy to an appropriate physician consultation. The purpose is to understand the evidence, regulatory status, risks, and established alternatives. A consultation does not guarantee that a particular product will be prescribed.
Medication billing depends on the treatment prescribed. FDA-approved commercially manufactured medications may be filled through a retail or specialty pharmacy and may be eligible for insurance coverage depending on the patient’s plan. When a compounded medication is clinically appropriate and lawfully available, it is dispensed by an appropriately licensed compounding pharmacy and billed separately from Empower Med’s physician fees. Compounded preparations are not commercially manufactured drug products. They are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing. Empower Med does not guarantee that a compounded medication will be prescribed or available.
Hormone-medication billing may occur through the practice when Empower Med handles medication management and procurement; charges remain itemized.
Labs are ordered through Empower Med and billed separately at the published patient prices shown on the Labs page. Written interpretation and consultation fees depend on the tier selected and are never embedded in a physician fee.
When two eligible service lines — Metabolic, TRT, or HRT — are managed together, one physician fee is billed at the standard rate and the second eligible physician fee is reduced by 25%. For equal-priced HRT and TRT, either may be designated the discounted second line. Initial evaluations, labs, medications, and pharmacy charges are not discounted and remain itemized separately.
For example, when two eligible service lines are managed together, one physician fee is billed at the standard rate and the second eligible physician fee receives the published 25% combined-care discount.
Yes, for Metabolic and TRT. Prior Open-Access Lab customers receive a $100 credit toward their first Metabolic month (net $25 physician fee for that first month) or a $165 credit toward their first TRT month (covers the $149 physician fee in full, with $16 rolling to cycle 2).
There is no lab credit for HRT by design — HRT entry is symptom-driven and cardiovascular-risk-driven, not lab-driven.
Yes. Existing patients receive a $50 credit toward a future order, lab purchase, or month of physician care after a new patient they referred completes their first paid service. Credit expires 12 months after issuance. No cap on referrals.
Every Empower Med charge appears as EMPOWER MED MEDICAL / DUMFRIES VA — a physician practice line, not a pharmacy line. When a dispensing pharmacy bills a medication directly, that charge appears under the pharmacy’s own descriptor, separately from Empower Med clinical fees.
Yes. You may cancel at any time, with no early-termination fee. Fees already paid are nonrefundable. Ending care ends the active physician-patient and monitoring relationship, so Empower Med cannot authorize additional TRT, HRT, or other ongoing prescription treatment after care ends.
For TRT specifically, continued prescribing requires active care, required evaluations, laboratory monitoring, follow-up, and applicable controlled-substance and clinical-safety requirements. If you plan to continue treatment elsewhere, arrange continuity with another qualified clinician before ending care.
Your clinical records are retained per applicable Virginia medical-records retention requirements. See the Notice of Privacy Practices for details on how your PHI is handled.
Testosterone is a DEA Schedule III controlled substance. Safe delivery requires baseline labs (Total T, Free T, Bioavailable T, SHBG, CBC, HbA1c, LH, PSA, TSH, Lipid Panel), ongoing hematocrit and PSA monitoring, and protocol titration based on how your body responds. These monitoring elements support safer, individualized TRT management and guide treatment adjustments over time.
Endocrine society guidance and the recent perimenopause literature are clear: FSH and estradiol levels in women 45+ are too volatile to reliably rule in or rule out the transition. Protocols that hinge on these single values miss the patient entirely. Empower Med’s HRT labs focus on what actually drives the protocol — cardiovascular risk (BMP, Lipid Panel, HbA1c) and VTE history.
Every patient at Empower Med begins with a documented physician evaluation — a virtual consultation with a physician — before any medication is authorized. Medication is authorized only after a documented clinical evaluation and when it is medically appropriate for the individual patient.
